Full Press Release Details
DUBLIN , July 13, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that Zepzelca ™ (lurbinectedin) was added by the National Comprehensive Cancer Network (NCCN ® ) to the Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for small cell lung cancer (SCLC) on July 7, 2020 .
The U.S. Food and Drug Administration (FDA) approved Zepzelca under accelerated approval on June 15, 2020 for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy. 1 The approval was based on the data from the open-label, single-arm monotherapy trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
The NCCN Guidelines for SCLC now include lurbinectedin as a recommended regimen for both patients who relapse six months and less after prior systemic therapy and for patients who relapse more than six months after prior systemic therapy. For patients who relapse six months and less, lurbinectedin is a preferred regimen.
About Zepzelca ™ (lurbinectedin) Zepzelca , also known as PM1183, is an alkylating drug that binds guanine residues within DNA. This triggers a cascade of events that can affect the activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in disruption of the cell cycle and eventual cell death. 1
Zepzelca for injection 4 mg is a prescription medicine used to treat adults with a kind of lung cancer called small cell lung cancer that has spread to other parts of the body (metastatic) and who have received treatment with chemotherapy that contains platinum, and it did not work or is no longer working. Zepzelca is approved based on response rate and how long the response lasted. Additional studies will further evaluate the benefit of Zepzelca for this use.
Important Safety Information
Before receiving ZEPZELCA, tell your healthcare provider about all of your medical conditions, including if you:
Males with female partners who are able to become pregnant should use effective birth control during treatment with and for 4 months after your final dose of ZEPZELCA.
Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how ZEPZELCA works.
What should I avoid while using ZEPZELCA?
Avoid eating or drinking grapefruit, or products that contain grapefruit juice during treatment with ZEPZELCA.
ZEPZELCA can cause serious side effects, including:
Your healthcare provider may temporarily stop treatment, lower your dose, or permanently stop ZEPZELCA if you develop low blood cell counts or liver problems during treatment with ZEPZELCA.
The most common side effects of ZEPZELCA include:
These are not all of the possible side effects of ZEPZELCA.
Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Jazz Pharmaceuticals at 1-800-520-5568.
More information about Zepzelca, including Full Prescribing Information and Patient Information, is available here .
ZEPZELCA is a trademark of PharmaMar, S.A. used by Jazz Pharmaceuticals under license.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
References: 1. ZEPZELCA (lurbinectedin) Prescribing Information. Palo Alto, CA : Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals Media and Investor Relations Contact Media Contact: Jacqueline Kirby , Vice President, Corporate Affairs & Government Relations Ireland +353 1 697 2141 U.S. +1 215 867 4910
Investor Contact: Kathee Littrell , Vice President, Investor Relations Ireland +353 1 634 7887 U.S. +1 650 496 2717
SOURCE Jazz Pharmaceuticals plc